Unfortunately, yet another report reveals the dearth of women and minorities, especially African Americans’ representation in clinical trials in the critically important cardiovascular and metabolic therapeutic domain. The results of a recent study published in the Journal of the American Heart Association—part of the American Heart Association—reveals that various demographic groups continue to be “underrepresented” in the study of novel cardiometabolic medications with no real evidence of improvement with enrollment numbers over the past decade. This possibly is part of a worsening trend where a bifurcated world exists—with overall declining life expectancy, at least in America, is driven by issues associated with the social determinants of health. A tale of two worlds emerge.
Cardiovascular and cardiometabolic diseases (combining both cardiovascular and metabolic) represent the leading cause of death around the world. With Type 2 diabetes involved, such risks increase the risk of cardiovascular disease four-fold in women.
Minority groups such as Blacks, Hispanics, and Native Americans face higher probabilities of facing these diseases. As rese...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).